IsoPlexis to Present First-of-Its-Kind Data on Simultaneous Single Cell TCR Profiling and Highly Multiplexed Functional Proteomics at AACR 2022
April 08 2022 - 7:00AM
IsoPlexis Corporation (NASDAQ: ISO), the Superhuman Cell
Company, today announced that data generated using its Duomic™
platform demonstrates the ability to connect T Cell Receptor (TCR)
diversity to the most functionally potent single cells. This
enables a wide variety of applications for tumor infiltrating
lymphocytes, personalized neoantigen TCR’s, cancer immunology in
terms of understanding antigen specificity, as well as T cell
potency. The data will be presented at the 2022 Annual Meeting of
the American Association for Cancer Research (AACR), which will
take place April 8-13, 2022 at the Ernest N. Morial Convention
Center in New Orleans, Louisiana.
At AACR, IsoPlexis will reveal details on the data obtained
using its single-cell Duomic TCR platform, which enables
simultaneous profiling of highly multiplexed functional proteomic
cytokines and TCR repertoires/TCR clonotypes as well as
identification of specific TCR V(D)J recombinations with functional
cell clusters across the same individual T cells. The combination
of these two classes of analytes at the single cell level provides
a key new modality for tracking the most potent and
antigen-specific immune cells together to fight cancer and
infectious disease, for the first time. It is now known that these
powerful single-cell subsets of highly functional "superhero" cells
are critical to driving longer term response in cell and immune
therapies via functional
proteins.
The presentation, titled “First of its Kind T Cell Receptors and
Functional Proteomics Detected from the Same Single Cells to
Advance Cancer Immunology Discovery,” will take place on Monday,
April 11 from 1:30 p.m. – 5:00 p.m. Central Daylight Time (CST).
The presentation (# LB094 / 1) will be located in section 18 of the
Ernest N. Morial Convention Center.
Additionally, the multiple poster presentations from
Institutions such as Brown University, University of California,
Los Angeles, and other companies will also highlight novel
applications in chemotherapy-induced senescent fibroblasts,
adoptive cell therapy, and next generation CAR-T therapies:
April 8, 2022, 12:00 PM - 1:00 PM
- 5297 - ONC201
suppresses cancer cell growth in a reconstructed tumor
microenvironment that includes chemotherapy-induced senescent
fibroblasts
April 12, 2022, 9:00 AM - 12:30 PM
- 2760 / 17 –
Hypophosphatemia due to increased effector cell metabolic activity
is associated with neurotoxicity symptoms in anti-CD19 CAR T cell
therapy
- 2821 / 12 -
Incorporation of intrinsic checkpoint blockade enhances
functionality of multigenic autologous UltraCAR-T® cells
manufactured using non-viral gene delivery and rapid manufacturing
process
About IsoPlexis
IsoPlexis is the Superhuman Cell company.
IsoPlexis’ systems uniquely identify a comprehensive range of
multifunctional single cells, i.e. the superhero cells in the human
body. These cells enable researchers to understand and predict
disease progression, treatment resistance and therapeutic efficacy
to advance all of human health.
IsoPlexis has been named Top Innovation or Design by The
Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple
others. The IsoPlexis platform is used globally by researchers,
including those at the top 15 global pharmaceutical companies and
at two-thirds of leading U.S. comprehensive cancer centers.
Cautionary Note Regarding Forward Looking
Statements
Certain statements in this press release are forward-looking
statements that are subject to risks and uncertainties that could
cause results to be materially different than expectations. Forward
looking statements may be identified, in part, by use of words such
as “is”, “will”, ”enables”, or “may”. Important factors that could
cause actual results to differ materially include: the rate of
adoption of the Company's technology by its customers and potential
customers as well as the risk factors set forth in the Risk Factors
section of the Company's prospectus filed with the SEC. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, IsoPlexis disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
Investor Contact
investors@isoplexis.com
Press Contact
press@isoplexis.com
Related Links
www.isoplexis.com
SOURCE IsoPlexis
IsoPlexis (NASDAQ:ISO)
Historical Stock Chart
From Jun 2024 to Jul 2024
IsoPlexis (NASDAQ:ISO)
Historical Stock Chart
From Jul 2023 to Jul 2024